Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
Date:4/29/2009

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved for commercial sale. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medarex to Present at the Needham Cancer Therapeutics Conference
2. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Medarex to Present at the RBC Capital Markets Healthcare Conference
6. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
7. Medarex Announces 2008 Third Quarter Financial Results
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. Medarex to Present at the UBS Global Life Sciences Conference
10. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
11. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... and CINCINNATI , ... plc (LSE: SHP, NASDAQ: SHPG ) and ... three-year, broad research collaboration for rare diseases. The goal ... novel therapies to treat rare diseases with high ... capabilities with Cincinnati Children,s research expertise. As a ...
(Date:3/26/2015)... 26, 2015 PAREXEL International Corporation ... clinical research organization , announced today that ... to acquire all of the business assets of ... provider of specialized pharmacovigilance services, based in ... detection, assessment, monitoring, and prevention of adverse ...
(Date:3/26/2015)... America," the popular news television program that airs in numerous ... film actor James Earl Jones, has announced that it will ... , Botany is commonly described as the scientific study of ... more complicated than that. Scientists and other professionals study a ... smallest bacteria known to man to the largest trees that ...
(Date:3/26/2015)... NJ (PRWEB) March 26, 2015 WriteResult, ... partnered with researchers from Yale University’s School of Public ... by study participants during a 4 month-long project. The ... of providing low income families with free access to ... habits and diet-related health concerns like high blood pressure, ...
Breaking Biology Technology:Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3
... Aug. 16 /PRNewswire-FirstCall/ Carrington Laboratories,Inc., a global provider ... today that it received a letter from The,Nasdaq ... determined to,delist the securities of the Company, and ... of the open of business on Thursday, August,16, ...
... tools and information to sustain ... and testing, PHILADELPHIA, Aug. 17 Roche representatives,will ... Saturday,August 18 - Sunday, August 19 to educate the ... factors, the importance of getting,tested and possible treatment options. ...
... 17 Emisphere,Technologies, Inc. (Nasdaq: EMIS ) announced ... million shares of common stock and warrants to,purchase 0.4 ... of $3.785,per unit. The five-year warrants will be exercisable ... at an exercise price of $3.948 per share. ...
Cached Biology Technology:Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets 2Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community 2Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community 3Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering 2
(Date:3/17/2015)... , March 17, 2015 Emotient, ... analytics software, today announced general availability of ... service for the analysis of facial expressions. The ... advertising, media content, products and services. It delivers ... engagement and sentiment - as derived from facial ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
(Date:3/11/2015)... 2015   The Sync Project™ today ... measure and harness music to improve health. The ... objective measurements of physiology, enabling the study of ... large populations. It is designed for medical and ... rigorous studies and accelerate the discovery of the ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... French . Scientists at the Omics Science ... along with researchers from McGill University and other institutions worldwide ... in mammals. Three years of intensive research by members of ... several milestone scientific papers in Nature Genetics and ...
... Abboud began his work at the University of Iowa in ... the brain and the blood vessels. His research since has ... flow to meet the body,s constantly changing demands. The ... be on the way: Dr. Abboud defined the identity of ...
... of the status of conservation efforts in the United ... just-released database that allows wildlife and conservation professionals to ... protected areas. Several federal, state, and non-government agencies ... the Protected Areas Database United States (PAD-US). ...
Cached Biology News:Major international study challenges notions of how genes are controlled in mammals 2Translating the conversation between the brain and blood vessels 2Translating the conversation between the brain and blood vessels 3What's protected, what's not? 2What's protected, what's not? 3
... used to study co-translational and initial ... such as signal peptide cleavage, membrane ... be examined by the translation of ... the presence of these microsomal membranes. ...
... need to make your strain of cells ... advantage of Lucigen’s unrivalled expertise in producing ... Service offers: Chemically competent or ... Fast turnaround Quality control ...
... Certify products ATP-Free using Mo Bio luciferase assay. ... certification service that will allow you to certify ... accuracy and enable you to deliver them to ... Bios ATP detection limit is 3.5 x 10-12 ...
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Biology Products: